Published in Age Ageing on December 15, 2006
Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart (2012) 1.38
The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2011) 1.14
Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. Medicine (Baltimore) (2015) 0.90
Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat (2011) 0.87
Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open (2014) 0.87
Antiplatelets versus anticoagulants for the treatment of cervical artery dissection: Bayesian meta-analysis. PLoS One (2013) 0.86
The case for an elderly targeted stroke management. Front Neurol (2011) 0.86
Prevention of cardioembolic stroke. Neurotherapeutics (2011) 0.85
Comment on the European guidelines for the management of atrial fibrillation. Clin Res Cardiol (2011) 0.84
Use of antithrombotic medications among elderly ischemic stroke patients. Circ Cardiovasc Qual Outcomes (2010) 0.83
Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. Int J Gen Med (2013) 0.83
Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach. Aging Dis (2012) 0.82
Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation? Clin Interv Aging (2014) 0.81
Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. J Saudi Heart Assoc (2014) 0.80
Effectiveness and safety of warfarin and anti-platelet drugs for the primary prevention of stroke in patients with non-valvular atrial fibrillation: a meta-analysis. Int J Clin Exp Med (2015) 0.80
Anticoagulation for stroke prevention in elderly patients with atrial fibrillation: risk-benefit ratio remains highly favorable. J Vasc Interv Neurol (2010) 0.80
Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol (2016) 0.80
Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum Beta-lactamase-producing organisms: a systematic review of the clinical evidence and health services impact. CADTH Technol Overv (2013) 0.78
Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J Interv Card Electrophysiol (2009) 0.77
Outpatient management of oral anticoagulation therapy in patients with nonvalvular atrial fibrillation. Bosn J Basic Med Sci (2009) 0.77
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev (2013) 0.77
How to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion. Postepy Kardiol Interwencyjnej (2015) 0.76
Antithrombotic therapy - predictor of early and long-term bleeding complications after transcatheter aortic valve implantation. Arch Med Sci (2013) 0.76
Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. Med Devices (Auckl) (2015) 0.76
Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study. BMC Cardiovasc Disord (2016) 0.75
Novel stroke risk reduction in atrial fibrillation: left atrial appendage occlusion with a focus on the Watchman closure device. Vasc Health Risk Manag (2017) 0.75
Warfarin versus aspirin in the elderly in primary prophylaxis for atrial fibrillation. Age Ageing (2007) 0.75
Stroke prevention: age alone does not rule out warfarin. J Fam Pract (2007) 0.75
Antithrombotic therapy in cardiac embolism. Curr Cardiol Rev (2010) 0.75
Comment on the WASPO study. Age Ageing (2007) 0.75
Anticoagulation for atrial fibrillation in the elderly: part 2. Curr Atheroscler Rep (2008) 0.75
Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect. PLoS One (2016) 0.75
Recent Atrial Fibrillation Guidelines - Looking at Both Sides of the Atlantic. Arrhythm Electrophysiol Rev (2013) 0.75
Antithrombotic management of atrial fibrillation in the elderly. Med Clin North Am (2015) 0.75
Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. J Blood Med (2012) 0.75
Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial. Trials (2017) 0.75
Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open (2017) 0.75
[Stroke and atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2009) 0.75
[Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?]. Herzschrittmacherther Elektrophysiol (2009) 0.75
Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J (2012) 2.89
Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J (2005) 2.34
The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab (2004) 2.34
Low serum testosterone and increased mortality in men with coronary heart disease. Heart (2010) 2.14
Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care (2007) 2.12
Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care (2011) 1.91
The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail (2006) 1.60
Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond) (2006) 1.60
Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res (2008) 1.54
Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol (2013) 1.47
Improving the management of acute myocardial infarction. BMJ (2002) 1.39
Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J (2003) 1.29
Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol (2002) 1.17
Heart failure as an inflammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail (2002) 1.14
Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs (2005) 1.12
Rate control in permanent atrial fibrillation. BMJ (2007) 1.11
The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol (2003) 1.04
Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun (2004) 1.04
Reversible heart failure: toxins, tachycardiomyopathy and mitochondrial abnormalities. Postgrad Med J (2012) 0.99
A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur J Endocrinol (2004) 0.98
Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation (2007) 0.98
Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. Eur J Endocrinol (2003) 0.96
Testosterone and cardiovascular disease in men. Asian J Androl (2012) 0.94
Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonism action. Clin Sci (Lond) (2004) 0.94
Testosterone in chronic heart failure. Front Horm Res (2009) 0.92
The influence of testosterone upon vascular reactivity. Eur J Endocrinol (2004) 0.92
Testosterone and coronary artery disease. Front Horm Res (2009) 0.91
A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J (2004) 0.88
Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes (2010) 0.88
Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc Health Risk Manag (2008) 0.84
Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care (2008) 0.83
Study protocol to investigate the effects of testosterone therapy as an adjunct to exercise rehabilitation in hypogonadal males with chronic heart failure. BMC Cardiovasc Disord (2006) 0.83
Bio-available testosterone levels fall acutely following myocardial infarction in men: association with fibrinolytic factors. Endocr Res (2002) 0.83
Association analysis of IL-12B and IL-23R polymorphisms in myocardial infarction. J Mol Med (Berl) (2007) 0.82
Mechanisms of agonist-induced constriction in isolated human mesenteric arteries. Vascul Pharmacol (2006) 0.82
Endogenous testosterone levels and cardiovascular disease in healthy men. Heart (2011) 0.81
Effect of testosterone therapy on QT dispersion in men with heart failure. Am J Cardiol (2003) 0.81
Cytomegalovirus seropositivity, infectious burden, and coronary artery disease. Am Heart J (2003) 0.79
Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: further supportive data. J Clin Endocrinol Metab (2003) 0.79
Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure. Endocr Res (2005) 0.78
Reversible heart failure: the role of inflammatory activation. Postgrad Med J (2010) 0.78
Effect of Testosterone on Inflammatory Markers in the Development of Early Atherogenesis in the Testicular-Feminized Mouse Model. Endocr Res (2012) 0.77
Intrinsic responses of rat coronary arteries in vitro: influence of testosterone, calcium, and effective transmural pressure. Endocrine (2002) 0.76
Coronary angioplasty versus fibrinolytic therapy in acute myocardial infarction. N Engl J Med (2003) 0.76
Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. Cardiovasc Ther (2009) 0.76
Mechanisms of agonist-induced constriction in isolated human pulmonary arteries. Vascul Pharmacol (2009) 0.76
The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction. Clin Auton Res (2002) 0.76
Replacement therapy, not recreational tonic. Nature (2004) 0.75
Depression and outcome after coronary artery bypass surgery. Lancet (2002) 0.75
Colonic stenting: an alternative to surgery in the elderly. Age Ageing (2007) 0.75
Coronary artery disease in men: the role of sex hormones. Future Cardiol (2006) 0.75
Focal pulmonary oedema: an unusual presentation of acute mitral regurgitation. Thorax (2012) 0.75
Starting warfarin as an outpatient. Br J Gen Pract (2002) 0.75
Current issues in thromboprophylaxis in the elderly. Drugs Aging (2008) 0.75